Full-Time
Clinical Trial Supply Manager
Posted on 8/15/2026
Novartis
10,001+ employees
Global pharmaceutical company delivering science-based innovations
No salary listed
Hyderabad, Telangana, India
In Person
Bachelor's, Master's, MBA, PhD
 Biology & Biotech (1) |
|---|
Get referred to Novartis
See people who can refer or advise you
- > 5 years of practical experience in clinical supplies within the pharmaceutical industry.
- Strong operational excellence with high attention to detail, advanced project management, organization, and planning skills.
- Broad technical knowledge of supply chain systems used for forecasting and demand planning, including at least 3 years of expertise with SAP.
- Data and digital savviness with high learning agility.
- Knowledge of relevant regulations, including Good Manufacturing Practice and Health, Safety, and Environment requirements.
- A Master's or Doctorate in life sciences, or an MBA with a bachelor's degree, or equivalent experience in life science.
- Represent Global Clinical Supply as a core member of the Clinical Trial Team and define and advise on the optimal clinical trial supply strategy.
- Review clinical trial protocols and amendments and provide input on packaging design, clinical trial supply design, and visit schedules.
- Create and maintain accurate clinical supply demand for assigned studies using protocol requirements, study parameters, milestones, patient projections, overage, defined processes, and systems.
- Create and drive finalization of packaging designs and comprehensive label strategies for participating countries.
- Define clinical supply parameters for Interactive Response Technology setup and initiate updates throughout the clinical trial.
- Develop and execute a trial-level project plan with relevant roles.
- Identify, assess, and communicate supply risks with mitigation strategies to ensure supply continuity.
- Collaborate with line-function partners on country submission and approval timelines to develop the supply strategy.
- Generate distribution plans for investigational medicinal products and trigger and track shipments from central depots to regional and local depots.
- Develop, maintain, and execute resupply strategies with proactive planning, lead times, replenishment quantities, compliance, supply continuity, and expiry management.
- Consolidate, maintain, and track the clinical trial budget for Global Clinical Supply external costs, including labels, packaging, distribution, and comparators.
- Contribute as a full member of the Global Clinical Supply sub-team and facilitate knowledge and information exchange with the Clinical Trial Team.
- Prepare the Global Clinical Supply project lead to address supply considerations in cross-functional teams.
- Continual Improvement Process.
- Master Data.
- Materials Management.
- Production Planning.
- Technical Requirements.
- Waterfall Model.
Novartis is a global pharmaceutical company that uses science-based innovations to develop treatments and improve patient outcomes worldwide. Its products are medicines developed through research and development to address various diseases, aiming to reach nearly 1 billion people. The company differentiates itself by large-scale investment in R&D, a global presence with a diverse workforce, and a clear mission to Reimagine Medicine, focusing on meeting the changing needs of patients. Its goal is to improve quality of life and extend life expectancy by delivering meaningful therapies through its research and development efforts.
Company Size
10,001+
Company Stage
IPO
Headquarters
Basel, Switzerland
Founded
1970
Get referred to Novartis
See people who can refer or advise you
Simplify's Take
What believers are saying
- Remibrutinib beat teriflunomide in two Phase III MS trials on September 2, 2026.
- Novartis and Alteogen can unlock up to $3.223 billion from subcutaneous launches.
- Novartis plans $23 billion of U.S. manufacturing investment over five years, strengthening supply resilience.
What critics are saying
- Rap-cel pauses on August 24, 2026 follow three deaths and damage autoimmune ambitions.
- Entresto patent expiry threatens a major revenue pillar during 2026-2028.
- Basel relocation cuts about 130 jobs by 2028, signaling execution risk and internal disruption.
What makes Novartis unique
- Novartis pairs blockbuster-scale biologics with remibrutinib, a 2026 oral MS candidate.
- Its Basel campus still anchors integrated discovery, development, and commercialization across therapeutic areas.
- The September 2, 2026 Alteogen deal broadens subcutaneous delivery options for multiple products.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
Disability Insurance
401(k) Retirement Plan
401(k) Company Match
Paid Vacation
Paid Sick Leave
Paid Holidays
Hybrid Work Options
Growth & Insights and Company News
6 month growth
↓ -5%1 year growth
↓ -5%2 year growth
↓ -5%Novartis (NYSE:NVS) shares gap up - time to Buy? Novartis AG (NYSE:NVS - Get Free Report) gapped up prior to trading on Tuesday. The stock had previously closed at $152.06, but opened at $162.15. Novartis shares last traded at $161.64, with a volume of 1,164,231 shares. Stocks & Bonds Key Novartis news. Here are the key news stories impacting Novartis this week: * Remibrutinib cleared two Phase III multiple sclerosis trials. The oral drug significantly reduced annualized relapse rates versus teriflunomide (Aubagio) in relapsing multiple sclerosis and also showed favorable results on MRI lesion measures. Novartis said a combined analysis indicated a clinically meaningful delay in disability progression, strengthening the drug's potential commercial profile and supporting plans for global regulatory submissions. * The positive MS data are viewed as an important growth catalyst. Analysts and investors see remibrutinib as a potential future blockbuster in a large market, particularly because it outperformed an established treatment and reportedly showed no liver-safety signal. The results prompted a sharp prior-session rally and could improve confidence in Novartis' longer-term product pipeline. * Novartis signed a potential $3.2 billion Hybrozyme agreement with Alteogen. The deal could expand access to Alteogen's drug-delivery technology and support development or commercialization of future medicines, though the financial commitment and deal milestones may limit the near-term earnings benefit. * Novartis plans to relocate laboratory activities and shut down some Basel production operations, potentially affecting about 130 jobs. The restructuring may improve efficiency over time but creates near-term execution and employee-transition costs. * Novartis paused eight autoimmune and neurological cell-therapy trials after three patient deaths. The pauses raise safety, regulatory and development risks for the experimental rap-cel program and prompted a customer-related setback for Oxford BioMedica, though the issue is separate from remibrutinib. Wall street analyst weigh in. Several research analysts recently weighed in on NVS shares. Citigroup restated a "buy" rating on shares of Novartis in a research note on Wednesday, July 22nd. Weiss Ratings reiterated a "buy (b)" rating on shares of Novartis in a research note on Friday, July 24th. Seven investment analysts have rated the stock with a Buy rating, seven have given a Hold rating and two have given a Sell rating to the company's stock. According to data from MarketBeat, Novartis presently has an average rating of "Hold" and a consensus target price of $141.20. Discover more Exchange Traded Funds Novartis stock performance. The business's 50-day simple moving average is $155.48 and its two-hundred day simple moving average is $153.74. The company has a quick ratio of 0.67, a current ratio of 0.86 and a debt-to-equity ratio of 0.89. The firm has a market cap of $309.93 billion, a price-to-earnings ratio of 24.50, a P/E/G ratio of 3.14 and a beta of 0.45. Novartis (NYSE:NVS - Get Free Report) last posted its earnings results on Tuesday, June 30th. The company reported $2.41 EPS for the quarter. Novartis had a return on equity of 38.56% and a net margin of 23.29%.The firm had revenue of $14.95 billion for the quarter. As a group, sell-side analysts expect that Novartis AG will post 8.84 earnings per share for the current fiscal year. Institutional trading of Novartis. Institutional investors and hedge funds have recently made changes to their positions in the business. Morgan Stanley raised its position in Novartis by 14.9% during the fourth quarter. Morgan Stanley now owns 8,876,906 shares of the company's stock worth $1,223,860,000 after acquiring an additional 1,148,033 shares during the period. Fisher Asset Management LLC grew its position in shares of Novartis by 3.1% in the fourth quarter. Fisher Asset Management LLC now owns 7,465,850 shares of the company's stock valued at $1,029,317,000 after purchasing an additional 226,484 shares during the period. Bank of America Corp DE grew its position in shares of Novartis by 9.1% in the first quarter. Bank of America Corp DE now owns 4,962,794 shares of the company's stock valued at $758,067,000 after purchasing an additional 413,778 shares during the period. Auto Owners Insurance Co increased its stake in shares of Novartis by 13,687.0% during the fourth quarter. Auto Owners Insurance Co now owns 4,628,296 shares of the company's stock worth $638,103,000 after purchasing an additional 4,594,726 shares in the last quarter. Finally, Franklin Resources Inc. raised its position in shares of Novartis by 10.3% during the 4th quarter. Franklin Resources Inc. now owns 4,479,307 shares of the company's stock worth $617,562,000 after purchasing an additional 419,988 shares during the last quarter. 13.12% of the stock is currently owned by hedge funds and other institutional investors. About Novartis. Novartis is a Swiss multinational pharmaceutical company headquartered in Basel that researches, develops, manufactures and commercializes prescription medicines and related health-care products. Formed through the 1996 merger of Ciba-Geigy and Sandoz, Novartis operates globally and focuses on bringing therapeutics from discovery through clinical development to commercial markets worldwide. The company's activities center on innovative pharmaceuticals across several therapeutic areas, including oncology, immunology, cardiovascular and metabolic diseases, neuroscience and ophthalmology, alongside capabilities in advanced therapies such as biologics, cell and gene therapies. Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.
Novartis could cut about 130 jobs in Basel site relocation. Posted on September 2, 2026 · Last updated: September 2, 2026 Novartis plans to cut 130 Basel jobs in site relocation move. Novartis announces Basel job cuts amid site relocation. ZURICH, Sept 2 (Reuters) - Novartis could cut about 130 jobs in Switzerland as it relocates laboratory activities and shuts down some production in Basel, the Swiss drugmaker said on Wednesday. Details of the relocation plan. The company said it plans to transfer laboratories for biological cell banks, analytical testing procedures and technical development activities from Kleinbasel, an area of Basel, to its main campus in the city by the end of 2028. Laboratory transfers and production changes. As part of a previously planned relocation, Novartis will also stop small-scale production of biologics in Kleinbasel by the end of 2027. "We intend to move these activities to other existing biologics drug substance sites within our manufacturing network, specifically in Europe," the company told Reuters in an email. Alignment with lease expirations and development plans. The relocation aligns with the expiration of individual leases at the Kleinbasel site in 2029 and is part of a previously announced plan to establish a new biologics technical development centre on its main campus in Basel. The relocation was first announced in 2022 and currently, there are around 200 people employed at the site in Kleinbasel, the company said. Novartis investments and industry trends. Novartis has been investing heavily in sites in the United States as part of an industry-wide move to boost manufacturing in the country under pressure from the Trump administration. It plans to spend $23 billion to build and expand 10 facilities in the U.S. over the next five years. Impact on employees and support measures. The planned cessation of production in Kleinbasel and the resulting job cuts are subject to an information and consultation process, Novartis said. It added that it was committed to supporting affected employees through measures such as job centres, early retirement, and a social plan that has been extended until the end of 2028. Reporting credits. (Reporting by Marleen Kaesebier in Zurich and Bhanvi Satija in London Editing by Dave Graham, Kirsten Donovan) Key takeaways. * Around 130 jobs could be cut in Basel as Novartis centralises lab and production activities from Kleinbasel to its main campus by end-2028. (novartis.com) * Lab relocations (biological cell banks, analytical testing, technical development) will complete by end-2028; small-scale biologics production ceases by end-2027. (novartis.com) * Support measures include job centres, early retirement, and a social plan extended through end-2028; changes undergo consultation process. (novartis.com) * This aligns with lease expirations at Kleinbasel in 2029 and builds on Novartis's prior 2022 announcement to invest in biologics technical development on the main Basel campus. (novartis.com) * The shift reflects Novartis's broader strategy, including a $23 billion U.S. investment over five years to bolster its manufacturing and R&D footprint. (novartis.com) References. Frequently asked questions. How many jobs could Novartis cut in Basel? Why is Novartis relocating its Basel site? When will small-scale biologics production end in Kleinbasel? What support measures are in place for affected Novartis employees? Is the Novartis Basel relocation part of a larger investment strategy?
Novartis to cut up to 130 jobs in Basel. Published on September 2, 2026 The pharmaceutical company Novartis is cutting up to 130 jobs in Basel by the end of 2027. The reason, the company announced on Wednesday, is that it is discontinuing the small-scale production of biologics in the Kleinbasel district. In the future, other biologics sites around the world will take over the tasks of the Basel plant. The reason for discontinuing production is that individual lease agreements at the Kleinbasel site are coming to an end. Consequently, further operations will be relocated from the Kleinbasel district to the Novartis Campus on the opposite bank of the Rhine, according to the press release. These include laboratories for biological cell banks, analytical testing procedures and technical development activities. + Swiss pharma giant Novartis to cut over 500 jobs at Stein plant The move represents the next step in the previously announced plans to establish a new centre for the technical development of biologics on the campus, the press release continues. Full story here Are you the author? SWI swissinfo.ch - the international service of the Swiss Broadcasting Corporation (SBC). Since 1999, swissinfo.ch has fulfilled the federal government's mandate to distribute information about Switzerland internationally, supplementing the online offerings of the radio and television stations of the SBC. Today, the international service is directed above all at an international audience interested in Switzerland, as well as at Swiss citizens living abroad. 2026-05-06 Swiss drugmaker Novartis says it will cut around 220 jobs in Germany as part of the planned closure of a production site in Wehr by the end of 2028. +Get the most important news from Switzerland in your inbox Novartis says the production site in Wehr, Germany, which manufactures tablets and capsules, is no longer... 2026-05-04 Safaa Odah and Jimmy "Spire" Sseetongo are this year's winners of the Prix international de dessin de presse in Geneva. The Palestinian is being honoured for her humanitarian work in the Gaza Strip, the Ugandan for his cartoons critical of the government. + Get the most important news from Switzerland in your inbox "Our 2026... 2026-05-01 Development banks are becoming increasingly important in light of cuts to foreign aid by Western countries such as the United States and Switzerland. But how do these banks work, and what do they achieve for the Global South? Development banks are cooperative banks set up by states. Their aim is to promote development in other... 2026-04-30 The Swiss economy is showing timid signs of recovery, but does not yet appear to be at full strength: this is the indication that emerges from the barometer of the KOF Swiss Economic Institute. + Get the most important news from Switzerland in your inbox In April, the indicator stood at 97.9 points, 2.3 points... 2026-04-30 This is what it's about AI-generated, editorially reviewed High but steady salaries: The median full-time salary in Switzerland reached CHF 6,788 in 2022, continuing a long-term upward trend with relatively stable income distribution across earners since 2008. Inequality and differences persist: Salaries vary widely by region, education, industry, and gender - women still earn 9.5% less... 2026-04-27 The cyber threat environment in Switzerland has worsened significantly, an analysis by telecoms firm Swisscom has found. Artificial intelligence, geopolitical tensions and growing digital dependencies in particular are driving up risks for businesses. + Get the most important news from Switzerland in your inbox In a new report, Swiss telecoms provider Swisscom identified a significant... 2026-03-16 Swiss companies exported war materiel worth CHF948.2 million ($1.2 billion) in 2025. This means that last year's war materiel exports almost equalled the record figure of CHF955 million set in 2022. According to the State Secretariat for Economic Affairs (SECO), Germany was the largest buyer of the deliveries authorised by SECO in 2025, with exports... 2026-03-09 Vontobel has warned that Switzerland must avoid "over-regulation" as the government prepares to unveil sweeping reforms to its too-big-to-fail regime in the wake of Credit Suisse's collapse. Co-chief executive Christel Rendu de Lint, who leads one of Switzerland's larger listed banks and asset managers with CHF241 billion ($311 billion) in assets under management, said safeguarding...
Alteogen enters option and license agreement with Novartis for development and commercialization of hybrozyme(tm)-enabled subcutaneous products. Sep 02, 2026, 07:00 ET * Novartis obtains rights to develop and commercialize subcutaneous formulations for multiple products utilizing ALT-B4 * Alteogen's fourth licensing agreement signed this year further accelerating the expansion of the Hybrozyme(TM) platform DAEJEON, South Korea, Sept. 2, 2026 /PRNewswire/ - Alteogen Inc. (KOSDAQ: 196170), a leading biopharmaceutical company specializing in platform technologies, announced today that it has entered into an option and license agreement with Novartis for the development and commercialization of subcutaneous (SC) products utilizing ALT-B4 powered by Alteogen's Hybrozyme(TM) technology. Under the terms of the agreement, Novartis will have multiple options to obtain exclusive rights to develop and commercialize subcutaneous formulations for multiple Novartis products using Alteogen's ALT-B4 (berahyaluronidase alfa). ALT-B4 (berahyaluronidase alfa) is a proprietary recombinant human hyaluronidase developed using Alteogen's Hybrozyme(TM) platform technology. ALT-B4 enables the conversion of biologics typically administered via intravenous (IV) infusion into more convenient and rapid subcutaneous (SC) formulations. By temporarily depolymerizing hyaluronan in the extracellular matrix, ALT-B4 facilitates the rapid and efficient dispersion and absorption of co-administered therapeutics. The agreement demonstrates Novartis' commitment to innovating new options for patients and enhancing the treatment experience. If all options are exercised and all milestones are achieved, Alteogen would be eligible to receive up to US$3,223 million, including option exercise fees, development and commercial milestone payments, as well as royalties on net sales of products commercialized under the agreement. "Novartis is a world-leading pharmaceutical company at the forefront of the global healthcare industry and has evaluated the application of ALT-B4 across multiple modalities for subcutaneous formulation development. This agreement demonstrates the technological strength and commercial value of Alteogen's Hybrozyme(TM) platform," said Tae-Yon Chun, Ph.D., CEO of Alteogen. About Alteogen Alteogen Inc. is a South Korea-based biopharmaceutical company that focuses on the development and commercialization of novel biologics such as Antibody-Drug Conjugates (ADCs), biobetters, and biosimilars. Alteogen's portfolio includes clinical-stage long-acting therapeutic proteins and next-generation ADCs, developed by its proprietary NexP(TM)-fusion and NexMab(TM) platform technology, respectively. It also developed a proprietary recombinant human hyaluronidase enzyme utilizing Hybrozyme(TM) technology, which enables the large volume subcutaneous administration of drugs that are typically administered as an IV infusion. The company was founded in 2008 and listed on KOSDAQ (196170.KQ). Vivek Shenoy, Ph.D., MBA Chief Business Officer Phone: +1 805 570 8998 E-mail: [email protected] Siddharth Akolkar, MSc, MBA Business Development Director Phone: +1 862 235 8516 E-mail: [email protected] SOURCE Alteogen Inc.
Novartis shares surged approximately 6% to $161.10 on Tuesday after its oral drug remibrutinib met primary endpoints in two Phase 3 trials for multiple sclerosis. The treatment demonstrated fewer relapses and brain lesions compared to teriflunomide, without raising anticipated liver-safety concerns. Pooled trial data indicated the drug may slow disability progression, offering an additional advantage in the MS treatment market. Remibrutinib is currently marketed as Rhapsido for chronic hives, generating $64 million in second-quarter sales. Full trial results are scheduled for October, with global regulatory submissions to follow. At $161.10, Novartis shares trade 23.13% above their estimated fair value of $130.84. The rally occurred despite the company suspending eight rap-cel studies following three deaths from severe immune reactions, though that programme is separate from remibrutinib.